Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Danaher gets conditional South Korean regulatory nod for $21 billion GE biopharma unit deal

Published 04/02/2020, 03:03
Updated 04/02/2020, 03:05
© Reuters.  Danaher gets conditional South Korean regulatory nod for $21 billion GE biopharma unit deal
GE
-
DHR
-

SEOUL (Reuters) - South Korea's antitrust watchdog has approved Danaher Corp's (N:DHR) proposed $21.4 billion (£16.5 billion)acquisition of General Electric's (N:GE) biopharma division on condition that they sell certain assets to address monopoly concerns.

The U.S. medical equipment maker Danaher got conditional EU approval in December for the deal after agreeing to sell five businesses to address worries about competition.

GE (N:GE) agreed a year ago to sell its biopharma business to Danaher in the biggest strategy reversal under its Chief Executive Lawrence Culp.

"The merger of the two U.S. firms will likely have impact on South Korea's bioprocessing market, which heavily relies on imports of foreign goods," the Korea Fair Trade Commission (KFTC) said in a statement, citing potential price hikes and monopoly concerns over the merger.

The KFTC said the companies need to sell eight bioprocessing product assets to address monopoly concerns.

"If either GE or Danaher Corp dose not follow the KFTC's measures, the South Korea watchdog would take punitive measures including filing criminal charges and imposing fines until they fulfil our requests," an official at the KFTC said.

Both Danaher and GE were not available for comment outside normal business hours in the United States.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.